

Company Number: 211291

**European Institute of Women's Health Limited By Guarantee**

**Annual Report and Financial Statements**

**for the financial year 1st July 2020 ended 30 June 2021**

# European Institute of Women's Health Limited By Guarantee

## CONTENTS

	<b>Page</b>
Directors and Other Information	3
Directors' Report	4 - 10
Directors' Responsibilities Statement	11
Independent Auditor's Report	12- 13
Income and Expenditure Account	14
Balance Sheet	15
Reconciliation of Members' Funds	16
Cash Flow Statement	17
Notes to the Financial Statements	18- 20

## **European Institute of Women's Health Limited By Guarantee DIRECTORS AND OTHER INFORMATION**

<b>Directors</b>	Karen Ritchie (Resigned 10 May 2021) Maeve Cusack Barbra Dowling Janusz Janczukowicz Orla Sheils Nelson (Resigned 10 May 2021)
<b>Company Secretary</b>	Hilary Murphy
<b>Company Number</b>	211291
<b>Charity Number</b>	20035167
<b>Registered Office</b>	33 Pearse Street Dublin2
<b>Auditors</b>	Only Audit Limited Chartered Certified Accountants & Statutory Auditors 56 Lansdowne Road Ballsbridge Dublin4
<b>Bankers</b>	Bank of Ireland 2 College Green Dublin2
<b>Solicitors</b>	Young & Company 2 Charleston Road Rathmines Dublin6

# European Institute of Women's Health Limited by Guarantee

## DIRECTORS' REPORT

for the financial year ended 30 June 2021

The directors present their report and the audited financial statements for the financial year ended 30 June 2021.

### Principal Activity and Review of the Business

The objective of the European Institute of Women's Health (EIWH) is to promote the advancement of education and public awareness of women's and family health issues throughout Europe by conducting research, undertaking surveys, establishing and delivering training programmes, seminars and conferences on all aspects of health care.

The EIWH is a registered charity (number 20035167) and is governed by a board of directors nominated by members. Membership of the EIWH is open to individuals and organisations with an interest in women's and family health. EIWH has a membership base of individuals and organisations that contribute to the ongoing work of the EIWH. <http://www.charitiesregulatoryauthority.ie/en/cra/oageslhome>

Together with its members, the EIWH works to:

- Promote lifelong health in women and their families.
- Ensure quality and equity in health policy, research, treatment and care for all.
- Draw the attention of policymakers to the obstacles that women who belong to minority and disadvantaged groups face in obtaining a desirable health status.
- Empower individuals to play an active part in their own health management.
- Promote gender-specific bio-medical and socioeconomic research that addresses sex and gender-based differences, to ensure equal access to quality prevention, treatment and care for women and their families throughout their lifespan.

The EIWH aims to reduce inequalities in health, those due to gender, age and socioeconomic status, by highlighting that sex and gender are important determinants of health. The EIWH works to improve and promote the understanding that vulnerability to, onset and progression of specific diseases vary in men and women.

Key priorities of the EIWH include:

- ▶ Prevention of chronic diseases.
- ▶ Promotion of health and well-being and combating smoking and obesity in women.
- ▶ Promoting active and healthy ageing across the lifespan and increasing healthy life years.
- ▶ Ensuring access to high quality treatment and care across an individual's lifespan.
- ▶ Ensuring safety of medicines in pregnancy and lactation.
- ▶ Highlighting sex and gender in medicines regulation and medical education.
- ▶ Highlighting sex and gender in medicines regulation and medical education.
- ▶ Advocating for healthy pregnancies.
- ▶ Advocating for awareness of mental health issues, with a focus on managing depression.
- ▶ Advocating for sex and gender sensitive health systems.

The EIWH has an Expert Advisory Group appointed by our Board which guides EIWH policies and activities.

### Board Members

- Maeve Cusack, National Cancer Control Programme, Ireland
- Barbara Dowling, University of the Arts London, UK
- Janusz Janczukowicz, Lodz University, Poland
- Karen Ritchie, INSERM, Montpellier, France
- Orta Shiels, Trinity College, Dublin, Ireland

### Company Secretary

- Hilary Murphy

### Secretariat

- Peggy Maguire, Director General
- Vincent Herity, Financial Manager
- Vanessa Moore
- Rebecca Moore

### Board Activity

Members of the board of the EIWH are located Europe-wide therefore a bi-monthly meeting is hosted by teleconference and annually in person. The Annual face to face meeting took place as a webinar May 2021 as the Covid pandemic continues to impact face to face meetings. The meeting provided the opportunity to present, review and evaluate the activity undertaken by the EIWH in the preceding 12 months as well as agree an outline of the future activity, direction and priorities for the EIWH.

# European Institute of Women's Health Limited by Guarantee

## DIRECTORS' REPORT

for the financial year ended 30 June 2021

### Financial Overview

One of the main objectives of the board is to ensure the sustainability of the EIW. The main source of income for the EIW is through EU project funding. This is supplemented from time to time by a small amount of industry funding. EIW Treasurer Sinead Hewson, having examined the audited accounts, noted an improvement in the finances for financial year 2020-2021, compared to previous years. The board agreed to continue its focus on applying for project funding while examining further opportunities to diversify.

### Governance

The EIW initiated the review of its governance code to ensure compliance with the statutory Irish Governance Code for charities. The compliance form was completed and submitted to the Charity Regulator in January 2021

### Activity Overview 2020-2021

The EIW takes an active role in contributing to and shaping European policy on women's health and that of their families. The EIW is proud of its continuing partnership with and contribution to agencies including the World Health Organization (WHO), the European Medicines Agency, The EU Commission and the EU Parliament. The work of the EIW has helped to shape health policy that affects and benefits women Europe-wide. The EIW is wholly committed to continuing its role in promoting the importance of gender equality in health and social policy, research and care, and to ensure access to quality treatment and care for women across their life-course, regardless of their economic status.

### Representation: European Medicines Agency (EMA)

The EIW has been a member of the Patient and Consumer Working Party (PCWP) of the European Medicines Agency for the last 20 years. The Working Party provides recommendations to EMA human scientific committees on all matters of interest to patients and citizens in relation to the safe and effective use of medicinal products. The European Medicines Agency is the European Union (EU) body responsible for the scientific evaluation and approval of medicines developed by pharmaceutical companies. The EMA centrally reviews and approves innovative medicinal products, based on the clinical trial data supplied by the applicant organisation. This approval process is strictly defined and regulated by EU legislation. Once approved, the medicinal product receives a marketing authorisation for use in the EU and European Economic Area (EEA).

### Why the work of the EMA important to women's health?

Women are some of the heaviest users of medicines, starting early with birth control pills, and across their lifespan as longevity champions. Additionally, due to women's reproductive and their caring role in society, women have a specific interest in, but also knowledge to offer about medicines use for themselves and their families.

EIW liaised with the EMA on the organisation of the workshop on 22nd September 2020, on Safety of Medicines in Pregnancy and lactation. Hildrun Sundseth gave a presentation and Peggy and Rebecca participated in the virtual webinar. The report of the meeting can be accessed at <https://www.ema.europa.eu/en/activities/workshops/safec-use-medicines-during-pregnancy-lactation>

Reviewed EMA Regulatory Science Strategy 2025 and wrote EIW Press Release to welcome the inclusion of population groups such as pregnant and lactating women and older people in EMA's new Regulatory Science Strategy.

Reviewed EMA overview on patient information leaflets to ensure the information is user-friendly.

For more information about the EMA and the Patient and Consumer Working Party: [http://www.ema.europa.eu/ema/index.jsp?curl=pages/contacts/CHMP/people\\_listing\\_000017.jsp](http://www.ema.europa.eu/ema/index.jsp?curl=pages/contacts/CHMP/people_listing_000017.jsp)

### New EMA Regulatory Strategy

EIW contributed to the EMA consultation for the EMA Regulatory Strategy 2025, commenting on the need for EMA to consider certain vulnerable population groups such as pregnant and lactation women in the regulatory strategy, as well as older patient with several different medical conditions.

### Raising the issues about Safe use of Medicines during Pregnancy and Lactation with EMA

EIW President attended several EMA meetings to highlight the EIW work on the Safe Use of Medicines during Pregnancy and Lactation as outlined in the EIW Policy Brief. This issue is currently a neglected medical and public health need, as little or no information is available to pregnant and lactating women and their health professionals regarding which medicines are safe to take during this period.

EIW's efforts to highlight this regulatory and societal gap in public health, has resulted in the Innovative Medicines Initiative (IMI) to set up the Research Consortium called 'conCEPTion'. (See below)

# European Institute of Women's Health Limited by Guarantee

## DIRECTORS' REPORT

for the financial year ended 30 June 2021

### European Centre for Disease Control and Prevention (ECDC) - Technical Advisory Group on Vaccination uptake

EIWH continues to interact and support the European Centre for Disease Control and Prevention (ECDC) - Technical Advisory Group on Vaccination and the development of the ECDC Information portal which was launched in 2020. The portal will provide information on vaccination to health care professionals and the general public.

ECDC Patient group representation: The Commission launched a selection procedure to appoint the representatives of non-governmental organisation representing patients at the Advisory Forum of the European Centre for Disease Prevention and Control (ECDC). The EIWH application was successful and will participate in ECDC meetings four times per year representing patient organisations.

### The EU Commission Coalition for Vaccination

The EU Commission Coalition for Vaccination has been established and the EIWH is part of the network. Due to Covid-19 the face-to-face meeting of the Coalition for Vaccination was not able to take place but keep the network updated by email.

### EIWH, Member of the Joint Action Stakeholder group, vaccination.

The EIWH contributed to the Joint Action survey on prioritising research on vaccination and contributed to the survey on vaccination hesitancy. The EIWH will take part in the online annual meeting of the Joint Action in September 2020.

### Health Technology Assessment (HTA)

The EIWH is a member of the EU Commission HTA Stakeholder Pool and continued to take part in the online meetings.

### European Immunisation Week

The EIWH developed a key vaccination policy brief titled 'Women and Vaccination in the EU'. In support of the European Immunisation Week in April 2021, the EIWH re-issued this vaccination policy brief with a press release to media.

### Antimicrobial Awareness Day

The EIWH participated in the discussion of the Antimicrobial Awareness Day, held by the European Centre for Disease Control (ECDC) and Prevention November 2020. The growing resistance to many antibiotics is a public health threat that has been steadily increasing in recent decades. As a result, many common infections are becoming difficult or even impossible to treat, sometimes turning a simple infection into a life-threatening condition. Antibiotics are vital in reducing the risk of complications in complex medical intervention such as hip replacements, organ transplants, cancer chemotherapy and the care of premature babies. The EIWH partnered with the ECDC annually to raise awareness of the threat through targeted media relations on Antimicrobial Awareness Day.

### E.U. Projects

#### MyHealth Project

The EIWH is a partner in the project MyHealth which is funded by DG Sante. The EIWH is leading the Communication and Dissemination Work package. The main aim of MyHealth is to improve the healthcare access of vulnerable immigrants and refugees newly arrived in Europe, by developing and implementing models based on know-how of a European multidisciplinary network.

During the monthly teleconferences and AGMs, EIWH ensures that communication and dissemination is considered throughout the project, including during the development of tools, reports and other activities. The EIWH works to make the public documents accessible and user friendly to encourage dissemination. The EIWH and partners have been adjusting the communication strategy throughout the project to improve dissemination moving forward.

The EIWH conducted the legal and organizational mapping of partner countries on access to health services. The results are being used as part of the basis for an interactive map. This map was shared with the MigHealthCare project for use as their template as well. The map was designed to be user friendly throughout the application. The project was completed in July 2020 <http://www.healthonthemove.eu>

# European Institute of Women's Health Limited by Guarantee DIRECTORS' REPORT

for the financial year ended 30 June 2021

## GO NANO project -

### Governing nanotechnologies through societal engagement.

The EIWH is a partner in Go Nano project, managed by Vanesa Moore. The project enables co-creation between citizens, civil society organisations, industry, researchers and policy makers across Europe to align future nanotechnologies with societal needs and concerns. GoNano aims to demonstrate how researchers can work with public and professional stakeholders to create novel suggestions for future nanotechnology products. The goal is to co-create concrete product suggestions within the areas of **food, health and energy**, illustrate new opportunities for innovation and develop policy recommendations. The EIWH completed a literature review on nanotechnology gender and culture. The EIWH has completed a white paper on Gender and Nano technology and contributed to several other papers relating to Nano technology. GoNano - participated in numerous TCs for the GoNano conference, including planning sessions, sessions with the technical provider, facilitator meetings, regular TCS for updates, rehearsals, liaising with speakers and dealing with last minute changes, advertising the conference on social media, recording a video to advertise the EIWH presentation. These culminated in the three-part GoNano online conference at the end of October where EIWH were hosts for Day 1, *Gender and Diversity in Research and Innovation*. EIWH gave a presentation with the same title, as well as moderated the session. In addition, EIWH participated in two eConsortium meetings, a GoNano evaluation exercise, contributed to partner deliverables, attended the other two GoNano conferences, as well as regular partner collaborations. The project completed in December 2020 <http://gonano-project.eu/>.

### ConcePTION - use of medication during pregnancy and lactation

ConcePTION is a large 5-year landmark Innovative Medicines (IMI-2) research project funded in part by the European Community budget and contributions from pharmaceutical companies. Its aim is to build *a pan European ecosystem for generating, monitoring and providing robust information on medication safety in pregnancy and breast feeding*.

The project unites an unprecedented 88 organizations from 22 countries, including the European Medicines Agency, drug manufacturers, academia, public health organizations, researchers and teratology networks to innovate new solutions to a long neglected public health issue.

With a shared vision that there is a societal obligation to radically and rapidly reduce uncertainty about the safety of medication use in pregnancy and breastfeeding, the **ConcePTION** team will work to create sustainable solutions to the current information gap. Through better use of existing health data from routine, daily practice together with enhanced methods to collect patient-reported data, and with new research capabilities to predict and measure maternal medication in breast milk, the team hopes to close the current information gap. The EIWH is involved in several Work Packages and has a seat on the Management. Board of ConcePTION. For more information, please visit [www.imi-conception.eu/](http://www.imi-conception.eu/)

### VAS meeting

Vanessa represented the EIWH at the VAS-17 EADays conference in November, delivering a presentation in the PAD Strategic Network Session entitled *Women and Peripheral Artery Disease (PAD)*.

Represented EIWH at the European Public Health Alliance's Annual General Meeting in December and moderated the session on Re-election to the EPHA Board.

From September through to December, work continued on the EIWH edits of the WHO EMRO *Situation Analysis of Gender and Health in the Eastern Mediterranean Region*

### Successful Proposal submitted:

Revised proposal on Cervical Cancer prevention which has been renamed CCBIG SCREEN, the proposal got through the first stage evaluation and the second stage proposal was submitted in July 2020. EIWH will co-lead the Communication Work package with Inserm.

CCBIG SCREEN aims to create a projection model to evaluate targeted population based. interventions accounting for country-specific contextual factors such as costs and estimate impact according to improving coverage and participation in screening among women who are hard to reach and are at increased risk for Cervical Cancer. The proposal was successful, and the kick-off meeting took place in April 2021.

### EIWH National Focal Points

The EIWH is working to continue linking as well as strengthening its European and national activities and has been distributing the EIWH Manifesto to national health attaches and other Member State representatives in order to increase awareness of major health and social issues that affect women in Europe. The EIWH is working with organisations in other countries that are potential EIWH focal points in the future.

# European Institute of Women's Health Limited by Guarantee DIRECTORS' REPORT

for the financial year ended 30 June 2021

The Institute of Public Health, Austria, Department of Health Ireland and Charite, Germany are the first EIUH focal points and set an example of how further national focal points can be developed. The EIUH has identified further potential focal points and developed a terms of reference document for use in all Member States.

## Consultations

- Responded EU Commission Roadmap: Vaccination  
[https://ec.europa.eu/health/sites/health/files/vaccination/docs/2020\\_confidence\\_rep\\_en.pdf](https://ec.europa.eu/health/sites/health/files/vaccination/docs/2020_confidence_rep_en.pdf)
- **Responded EU Commission Roadmap on Violence against Women**  
[https://ec.europa.eu/smartregulationroadmaps/docs/2015\\_just\\_010\\_istanbu\\_convention\\_en.pdf](https://ec.europa.eu/smartregulationroadmaps/docs/2015_just_010_istanbu_convention_en.pdf)
- Responded to consultation EU Beating Cancer Roadmap.  
<https://ec.europa.eu/infolaw/better-regulation/have-your-say/initiatives/12154-Europe-s-Beating-Cancer-Plan/feedback?pid=6335574&page=34>
- Responded to consultation EU Phanna Strategy  
[https://ec.europa.eu/health/human-use/strategy\\_en](https://ec.europa.eu/health/human-use/strategy_en)
- Responded to consultation EU Commission Gender Equality Strategy  
[https://ec.europa.eu/info/policies/justice-and-fundamental-rights/gender-equality/gender-equality-strategy\\_](https://ec.europa.eu/info/policies/justice-and-fundamental-rights/gender-equality/gender-equality-strategy_)
- Responded to consultation WHO workplan 2021-2027  
<https://www.euro.who.in/en/health-topics/health-policy/european-programme-of-work>
- Responded to EU Commission consultation EU4Health Programme 2021-2025  
[https://ec.europa.eu/health/funding/eu4health\\_en](https://ec.europa.eu/health/funding/eu4health_en)
- Responded to European Public Health Alliance consultation on EU4Health <https://epha.org/eu4health>
- Prepared amendments to strengthen the health aspect in the Gender Equality Strategy and tabled by selected MEPs who were at our November EP meeting.
- Prepared amendments to strengthen the gender aspect in EU4Health programme, to establish a reference network on risk in pregnancy and tabled by selected MEP who was at our November EP meeting.

## Communications

The EIUH engages with media and the public to promote key initiatives and partnerships and to raise general awareness around major issues and conditions affecting women and their families. Outlined below is a sample of news releases issued by the EIUH in 2020 and 2021.

## Social Media

The EIUH has increased its social media presence by regular tweeting. For example: Tweeted in September, which was World Alzheimer month, Go Nano Tweets, World Cancer Day, European Cancer week, European Immunisation week.

## Publications - Policy Briefs

The European Institute of Women's Health generates policy briefs on many issues and makes recommendations for policy action. In keeping with the objective of the EIUH, policy briefings are developed following consultation with the Institute's network and are pertinent to women's health. Policy statements are distributed widely to stakeholders, policymakers and citizens and are available to view online at [www.eurohealth.ie](http://www.eurohealth.ie)

### The following policy briefs were completed during this period

Request for Briefing by Evelyn Regner -Chair of European Parliament (EP) Committee on Gender Equality (FEMM) Evelyn Regner approached us to complete a briefing on the impact of COVID-19 on women. We prepared the brief and sent to her office and also the office of the chair of the EP Environment and Public Health Committee and other MEP

Policy brief on Menstruation was updated to include LGBTI and current policy information on period poverty etc

### Policy Briefs/ position paper(s) in the works:

- Midlife and Older Women's Health will be completed in September 2021 with an online seminar to launch the report
- Maternal Health Report will be completed in April 2022. An online seminar will be held in January 2022 to discuss the findings

# European Institute of Women's Health Limited by Guarantee DIRECTORS' REPORT

for the financial year ended 30 June 2021

- Women as Carers across the be initiated in 2022

## Published articles

- Alzheimer's disease: <https://www.ncbi.nlm.nih.gov/oumed/31076376>
- Alzheimer's disease, [https://alzheimersanddementiajournal.com/article/S1552-5260\(18\)31837-5/pdf](https://alzheimersanddementiajournal.com/article/S1552-5260(18)31837-5/pdf)
- Gender FB for **MOPEAD** ; [https://17215c60-696c-4eb6-9adb-50cde843a50f.filesusr.com/ugd/e8882a\\_08fb25c1523345ed90dd6b3e32cede6b.pdf](https://17215c60-696c-4eb6-9adb-50cde843a50f.filesusr.com/ugd/e8882a_08fb25c1523345ed90dd6b3e32cede6b.pdf)

## EIWH membership/ Advisory Roles

The EIWH will continue in its role as advisor to the following:

- European Medicines Agency (EMA): Member of Patient and Consumer Working party, Ageing working group
- European Commission, DG SANTE: HTA Stakeholder pool
- DG SANTE: Member of the Joint Action -Vaccination Stakeholder platform
- European Centre for Disease Control and Prevention (ECDC): Formal Advisory Group Representing-Patients (Observer)
- European Centre for Disease Control and Prevention (ECDC) Technical Advisory Group on Vaccination Uptake
- European Public Health Alliance (EPHA): Board Member and former Presidency,
- European Patients Forum: Member of the Digital Advisory Group
- Member of Patient/Industry Think Tank of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
- WHO: Expert Advisor to and Member of the Expert Group on gender mainstreaming and WHO Women's Strategic Plan.
- Member of the WHO Academy Quality Committee Board
- Co-Chair - Women's Health task Force at the Department of Health Ireland
- Represent the Department of Health Ireland on the stakeholder Advisory group to A collaborative initiative between the International Agency for Research on Cancer (IARC/WHO), the Department of Health in Ireland and Health Service Executive's National Screening Service to support the delivery of an exemplar Cervical Cancer Screening Programme".
- Member of BBRMI Eric, a European research infrastructure for biobanking
- Fundamental Rights Agency: Member of the Stakeholder Platform
- Co-Chair of the Department of Health (Ireland), Women's Health Task Force  
Member, Department of Health (Ireland), Independent Patient Safety Council.

Request for Briefing by Evelyn Regner -Chair of European Parliament (EP) Committee on Gender Equality (FEMM) Evelyn Regner approached us to complete a briefing on the impact of COVID-19 on women. We prepared the brief and sent to her office and also the office of the chair of the EP Environment and Public Health Committee and other MEP

Policy brief on Menstruation was updated to include LGBTI and current policy information on period poverty etc

# European Institute of Women's Health Limited by Guarantee DIRECTORS' REPORT

for the financial year ended 30 June 2021

## Financial Results

The deficit for the financial year amounted to €(20,670) (2020 - €(53,582)).

At the end of the financial year, the company has assets of €214,938 (2020 - €53,920) and liabilities of €195,803 (2020 - €14,115). The net assets of the company have decreased by €(20,670).

## Directors and Secretary

The directors who served throughout the financial year, except as noted, were as follows:

Karen Ritchie (Resigned 10 May 2021)  
Maeve Cusack  
Barbra Dowling  
Janusz Janczukowicz  
Orla Sheils Nelson (Resigned 10 May 2021)

The secretary who served throughout the financial year was Hilary Murphy.

The company is limited by guarantee not having a share capital and therefore the directors or company secretary have no direct interest in the company.

In accordance with the Articles of Association, the directors retire by rotation and, being eligible, offer themselves for re-election.

## Future Developments

The directors are not expecting to make any significant changes in the nature of the business in the near future. At the time of approving the financial statements, the company remains exposed to the effects of the Covid-19 pandemic, however due to the nature of the company's activities the company has continued to operate and apply for projects and funding. In planning its future activities, the directors are aware that future funding for projects may become limited and will develop the activities of the company accordingly.

## Auditors

The auditors, Only Audit Limited, (Chartered Certified Accountants & Statutory Auditors) have indicated their willingness to continue in office in accordance with the provisions of section 383(2) of the Companies Act 2014.

## Principal risks and uncertainties

The principal risk the company is exposed to remains the availability of funding as this is dependent on external factors and is outside the control of the company. The directors consider that the principal risk in relation to funding is the outbreak of Covid 19 which has resulted in a significant slowdown in economic activity in Ireland and could impact future funding. Any such reduction in funding would impact the company's operations. The directors cannot fully quantify the effects of Covid 19 at the time of approving the financial statements. The company operates solely in the Republic of Ireland, therefore is not subject to currency risk. The company does not rely on significant borrowings and has minimal exposure to interest rate risk. The company's policy is to ensure that sufficient resources are available from cash balances and cashflows to ensure that all obligations can be met as they fall due.

## Statement on Relevant Audit Information

In accordance with section 330 of the Companies Act 2014, so far as each of the persons who are directors at the time this report is approved are aware, there is no relevant audit information of which the statutory auditors are unaware. The directors have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and they have established that the statutory auditors are aware of that information.

## Accounting Records

To ensure that adequate accounting records are kept in accordance with sections 281 to 285 of the Companies Act 2014, the directors have employed appropriately qualified accounting personnel and have maintained appropriate computerised accounting systems. The accounting records are located at the company's office at 33 Pearse Street, Dublin 2.

## Signed on behalf of the board

*Barbara Dowling*

sarora'owwnng \_\_\_\_\_  
Director

Date: 29/04/2022. \_ \_ \_ \_ \_

*Maeve Cusack*

\_\_\_\_\_  
Maeve Cusack  
Director

Date: 29/04/2022. \_ \_ \_ \_ \_

# European Institute of Women's Health Limited By Guarantee DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 30 June 2021

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the surplus or deficit of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and surplus or deficit of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014 and enable the financial statements to be readily and properly audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board

*Barbara Dowling*

*Maeve Cusack*

\_\_\_\_\_  
Barbra Dowling  
Director

\_\_\_\_\_  
Maeve Cusack  
Director

Date: 29/04/2022. \_\_\_\_ \_

Date: 29/04/2022. \_\_\_\_ \_

# **INDEPENDENT AUDITOR'S REPORT**

## **to the Members of European Institute of Women's Health Limited By Guarantee**

### **Report on the audit of the financial statements**

#### **Opinion**

We have audited the financial statements of European Institute of Women's Health Limited By Guarantee ('the company') for the financial year ended 30 June 2021 which comprise the Income and Expenditure Account, the Balance Sheet, the Reconciliation of Members' Funds, the Cash Flow Statement and notes to the financial statements, including the summary of significant accounting policies set out in note 2. The financial reporting framework that has been applied in their preparation is Irish Law and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", issued in the United Kingdom by the Financial Reporting Council, applying Section 1A of that Standard.

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 30 June 2021 and of its deficit for the financial year then ended;
- have been properly prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard; and
- have been properly prepared in accordance with the requirements of the Companies Act 2014.

#### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are described below in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard for Auditors (Ireland) issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and the Provisions Available for Audits of Small Entities, in the circumstances set out in note 5 to the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### **Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

#### **Other Information**

The directors are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our Auditor's Report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

#### **Opinions on other matters prescribed by the Companies Act 2014**

In our opinion, based on the work undertaken in the course of the audit, we report that:

- the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Directors' Report has been prepared in accordance with applicable legal requirements.

We have obtained all the information and explanations which, to the best of our knowledge and belief, are necessary for the purposes of our audit.

In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited and the financial statements are in agreement with the accounting records.

# INDEPENDENT AUDITOR'S REPORT

## to the Members of European Institute of Women's Health Limited By Guarantee

### Matters on which we are required to report by exception

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified any material misstatements in the directors' report.

The Companies Act 2014 requires us to report to you if, in our opinion, the requirements of any of sections 305 to 312 of the Act, which relate to disclosures of directors' remuneration and transactions are not complied with by the Company. We have nothing to report in this regard.

### Respective responsibilities

#### Responsibilities of directors for the financial statements

As explained more fully in the Directors' Responsibilities Statement set out on page 11, the directors are responsible for the preparation of the financial statements in accordance with the applicable financial reporting framework that give a true and fair view, and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, if applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the company or to cease operation, or has no realistic alternative but to do so.


#### Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the IAASA's website at: <[www.iaasa.ie/getmedia/b2389013-1cf6-458b-9b8f-a98202dc9c3a/Description\\_of\\_auditors\\_responsibilities\\_for\\_audit.pdf](http://www.iaasa.ie/getmedia/b2389013-1cf6-458b-9b8f-a98202dc9c3a/Description_of_auditors_responsibilities_for_audit.pdf)> The description forms part of our Auditor's Report.

#### The purpose of our audit work and to whom we owe our responsibilities

Our report is made solely to the company's members, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an Auditor's Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume any responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed.



Tracey Byrne

for and on behalf of

**ONLY AUDIT LIMITED**

Chartered Certified Accountants & Statutory Auditors

56 Lansdowne Road

Ballsbridge

Dublin 4

Date: 20 / 11 / 2014

# European Institute of Women's Health Limited By Guarantee INCOME AND EXPENDITURE ACCOUNT

for the financial year ended 30 June 2021

	Notes	2021 €	2020 €
Income		111,771	149,041
Expenditure		(132,441)	(202,623)
Deficit for the financial year		(20,670)	(53,582)
Total comprehensive income		(20,670)	(53,582)

Approved by the board on \_\_\_\_\_; and signed on its behalf by:

*Barbara Dowling*

*Maeve Cusack*

\_\_\_\_\_  
Barbra Dowling  
Director

\_\_\_\_\_  
Maeve Cusack  
Director

# European Institute of Women's Health Limited By Guarantee

## BALANCE SHEET

as at 30 June 2021

	Notes	2021 €	2020 €
<b>Current Assets</b>			
Work-in-progress	8	-	25,000
Cash and cash equivalents		214,938	28,920
		<u>214,938</u>	<u>53,920</u>
<b>Creditors: amounts falling due within one year</b>	9	(195,803)	(14,115)
<b>Net Current Assets</b>		<u>19,135</u>	<u>39,805</u>
<b>Total Assets less Current Liabilities</b>		<u>19,135</u>	<u>39,805</u>
<b>Reserves</b>			
Income and expenditure account		19,135	39,805
<b>Equity attributable to members of the company</b>		<u>19,135</u>	<u>39,805</u>

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

Approved by the board on Feb 16<sup>th</sup> and signed on its behalf by:

*Barbara Dowling*

*Maeve Cusack*

\_\_\_\_\_  
Barbra Dowling  
Director

\_\_\_\_\_  
Maeve Cusack  
Director

**European Institute of Women's Health Limited By Guarantee**  
**RECONCILIATION OF MEMBERS' FUNDS**

as at 30 June 2021

	<b>Retained surplus</b>	<b>Total</b>
	<b>€</b>	<b>€</b>
<b>At 1 July 2019</b>	93,387	93,387
Deficit for the financial year	<u>(53,582)</u>	<u>(53,582)</u>
<b>At 30 June 2020</b>	39,805	39,805
Deficit for the financial year	<u>(20,670)</u>	<u>(20,670)</u>
<b>At 30 June 2021</b>	<u><b>19,135</b></u>	<u><b>19,135</b></u>

# European Institute of Women's Health Limited By Guarantee

## CASH FLOW STATEMENT

for the financial year ended 30 June 2021

	Notes	2021 €	2020 €
<b>Cash flows from operating activities</b>			
Deficit for the financial year		<u>(20,670)</u>	<u>(53,582)</u>
		<b>(20,670)</b>	<b>(53,582)</b>
Movements in working capital:			
Movement in stocks		25,000	35,000
Movement in creditors		<u>181,688</u>	<u>(13,348)</u>
Cash generated from/(used in) operations		<u>186,018</u>	<u>(31,930)</u>
<b>Net increase/(decrease) in cash and cash equivalents</b>		<b>186,018</b>	<b>(31,930)</b>
<b>Cash and cash equivalents at beginning of financial year</b>		<b>28,920</b>	<b>60,850</b>
<b>Cash and cash equivalents at end of financial year</b>	<b>14</b>	<b><u>214,938</u></b>	<b><u>28,920</u></b>

# European Institute of Women's Health Limited By Guarantee

## NOTES TO THE FINANCIAL STATEMENTS

for the financial year ended 30 June 2021

### 1 General Information

European Institute of Women's Health Limited By Guarantee is a company limited by guarantee incorporated in the Republic of Ireland. 33 Pearse Street, Dublin 2 is the registered office, which is also the principal place of business of the company. The nature of the company's operations and its principal activities are set out in the Directors' Report. The financial statements have been presented in Euro(€) which is also the functional currency of the company.

### 2 Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

#### Statement of compliance

The financial statements of the company for the year ended 30 June 2021 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

#### Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

#### Income

All income resources are included in the Income and Expenditure Account when the charity is entitled to the income and the amount can be qualified with reasonable accuracy.

#### Expenditure

Expenditure is recognised on an accruals basis as a liability is incurred. Expenditure includes VAT which cannot be fully recovered and is reported as part of expenditure to which it relates.

#### Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	15% Straight line
----------------------------------	-------------------

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

#### Work in Progress

Work in Progress represents the value of work carried out to date on a project for which funds have not been received.

#### Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. In the Balance Sheet bank overdrafts are shown within Creditors.

#### Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

#### Taxation

No charge to current or deferred taxation arises as the company has been granted charitable status under Sections 207 and 208 of the Taxes Consolidation Act 1997, CHY number 12184.

# European Institute of Women's Health Limited By Guarantee

## NOTES TO THE FINANCIAL STATEMENTS

continued

for the financial year ended 30 June 2021

### 3. Departure from Companies Act 2014 Presentation

The directors have elected to present an Income and Expenditure Account instead of a Profit and Loss Account in these financial statements as this company is a not-for-profit entity.

### 4. Going concern

The company made a loss of €20,670, and has net members funds of €19,135 at the year end.

During the first quarter of 2020, The Covid-19 pandemic has spread throughout Ireland and has effected all aspects of the Irish economy and seen many restrictions on the movement of people. The company has adapted accordingly and continues to operate. The directors have secured funding until June 2020 and continue to look for new project and funding opportunities. The directors are confident that there is sufficient resources to enable them to continue to operate for the foreseeable future. On that basis the financial statements are prepared on a going concern basis.

### 5. Provisions Available for Audits of Small Entities

In common with many other businesses of our size and nature, we use our auditors to prepare and submit tax returns to the Revenue and to assist with the preparation of the financial statements.

### 6. Employees

The average monthly number of employees, including directors, during the financial year was 1, (2020 - 2).

### 7. Tangible assets

	Fixtures, fittings and equipment €	Total €
Cost		
At 1 July 2020	18,741	18,741
	<hr/>	<hr/>
At 30 June 2021	18,741	18,741
	<hr/>	<hr/>
Depreciation		
At 1 July 2020	18,741	18,741
	<hr/>	<hr/>
At 30 June 2021	18,741	18,741
	<hr/>	<hr/>
Net book value		
At 30 June 2021	-	-
	<hr/> <hr/>	<hr/> <hr/>

### 8. Stocks

	2021 €	2020 €
Work in progress	-	25,000
	<hr/> <hr/>	<hr/> <hr/>

### 9. Creditors

	2021 €	2020 €
Amounts falling due within one year		
Trade creditors	1,405	1,405
Taxation	12,918	6,268
Accruals	53,886	6,442
Deferred Income	127,594	-
	<hr/> <hr/>	<hr/> <hr/>
	195,803	14,115

# European Institute of Women's Health Limited By Guarantee

## NOTES TO THE FINANCIAL STATEMENTS

continued

for the financial year ended 30 June 2021

### 10. Status

The liability of the members is limited.

Every member of the company undertakes to contribute to the assets of the company in the event of its being wound up while they are members, or within one year thereafter, for the payment of the debts and liabilities of the company contracted before they ceased to be members, and of the costs, charges and expenses of winding up, and for the adjustment of the rights of the contributors among themselves, such amount as may be required, not exceeding€ 2.

### 11. Capital commitments

The company had no material capital commitments at the financial year-ended 30 June 2021.

### 12. Controlling interest

The company is controlled by the directors.

### 13. Post-Balance Sheet Events

In the first half of 2020, the Covid-19 virus spread worldwide. In common with many other countries, the Irish government issued guidance and restrictions on the movement of people designed to slow the spread of this virus. The company put the necessary conditions in place to enable the company to continue to operate during this period. The directors are confident that the company will be fully operational once the period of restriction is lifted. There have been no significant events affecting the company since the financial year-end.

### 14. Cash and cash equivalents

	2021	2020
	€	€
Cash and bank balances	<u>214,938</u>	<u>28,920</u>

### 15. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on \_\_\_\_\_.